ReviewFrontiers in bioengineering and biotechnology2025
Protein-based micro- and nano-transporters for gut microbiota modulators: advances in delivery strategies and gut health benefits.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanorobotic Approaches Against Multidrug-Resistant Infections: Design, Principle, Mechanistic Innovation, Translational Challenges and Biomedical Applications.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human gut microbiota (GM) is essential for gut health, and its dysbiosis is associated with diseases such as inflammatory bowel disease, obesity, and cancers. Natural GM modulators, including probiotics, bioactive phytochemicals, and peptides, have shown great potential in restoring microbial balance. However, their effectiveness is limited by stability, bioavailability, and targeted delivery to the gut. Protein-based micro- and nano-transporters have recently emerged as innovative platforms capable of overcoming these delivery barriers and improving the therapeutic performance of natural GM modulators. Here, we critically review the design strategies, functional performance, and therapeutic outcomes of various protein-based carriers, including composite hydrogels, stimuli-responsive microgels, targeted nanocomplexes, mucoadhesive microcapsules, and electrospun nanofibers. Furthermore, we discuss how these advanced systems ameliorate gut dysbiosis, modulate immune responses, enhance intestinal barrier integrity, and promote beneficial microbial growth. Finally, current challenges and future perspectives for clinical translation are outlined. Overall, this review aims to provide a mechanistic and practical foundation for the development of next-generation protein-based transporters for microbiota-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.